

Supplementary Table 7. met-QTL for the Coimbra, Portugal, cohort based on False Discovery Rate (q-vale < 0.05) – Controls only

Gene	rsID	CHRPOS (major/ minor)	Effect Allele	MAF	Super Pathway	Sub Pathway	Metabolite	Beta PT	P-value PT	Q-value PT
<i>C3</i>	rs11569547	19:6683622:C:T	T	0.064857	Amino Acid	Tyrosine Metabolism	dopamine 3-O-sulfate	0.335870675	1.17x10 ⁻⁵	0.493060846
<i>C1orf53</i>	rs72744974	1:197874385:A:T	T	0.115802	Lipid	Lysophospholipid	1-palmitoleoyl-GPC (16:1)*	-0.089311957	1.34x10 ⁻⁶	0.179789649
<i>C6orf15</i>	rs115997593	6:31144717:A:T	T	0.282481	Lipid	Phosphatidylethanolamine (PE)	1-oleoyl-2-linoleoyl-GPE (18:1/18:2)*	-0.168109467	1.19x10 ⁻⁶	0.179789649
<i>C6orf15</i>	rs147850080	6:31153020:T:C	C	0.283881	Lipid	Phosphatidylethanolamine (PE)	1-oleoyl-2-linoleoyl-GPE (18:1/18:2)*	-0.168109467	1.19x10 ⁻⁶	0.179789649
<i>C6orf15</i>	rs116587946	6:31154354:T:A	A	0.283876	Lipid	Phosphatidylethanolamine (PE)	1-oleoyl-2-linoleoyl-GPE (18:1/18:2)*	-0.168109467	1.19x10 ⁻⁶	0.179789649
<i>C6orf15</i>	rs150602567	6:31154434:C:T	T	0.283899	Lipid	Phosphatidylethanolamine (PE)	1-oleoyl-2-linoleoyl-GPE (18:1/18:2)*	-0.168109467	1.19x10 ⁻⁶	0.179789649
<i>C6orf15</i>	rs149853410	6:31163161:A:T	T	0.284349	Lipid	Phosphatidylethanolamine (PE)	1-oleoyl-2-linoleoyl-GPE (18:1/18:2)*	-0.168109467	1.19x10 ⁻⁶	0.179789649
<i>CCHCR1</i>	rs115883612	6:31183509:G:A	A	0.308248	Lipid	Phosphatidylethanolamine (PE)	1-oleoyl-2-linoleoyl-GPE (18:1/18:2)*	-0.152442672	2.64x10 ⁻⁶	0.19041804
<i>CCHCR1</i>	rs114276265	6:31187075:C:T	T	0.308247	Lipid	Phosphatidylethanolamine (PE)	1-oleoyl-2-linoleoyl-GPE (18:1/18:2)*	-0.152442672	2.64x10 ⁻⁶	0.19041804
<i>C6orf15</i>	rs1265094	6:31106893:A:G	A	0.431503	Lipid	Phosphatidylethanolamine (PE)	1-stearoyl-2-oleoyl-GPE (18:0/18:1)	0.095735782	9.83x10 ⁻⁷	0.179789649
<i>C6orf15</i>	rs116344411	6:31111675:C:A	C	0.436082	Lipid	Phosphatidylethanolamine (PE)	1-stearoyl-2-oleoyl-GPE (18:0/18:1)	0.095735782	9.83x10 ⁻⁷	0.179789649
<i>C6orf15</i>	rs115925201	6:31112075:G:A	G	0.436082	Lipid	Phosphatidylethanolamine (PE)	1-stearoyl-2-oleoyl-GPE (18:0/18:1)	0.095735782	9.83x10 ⁻⁷	0.179789649
<i>C6orf15</i>	rs114941286	6:31109882:G:T	G	0.468627	Lipid	Phosphatidylethanolamine (PE)	1-stearoyl-2-oleoyl-GPE (18:0/18:1)	0.095485524	2.43x10 ⁻⁶	0.19041804
<i>BTBD16</i>	rs11200536	10:124052216:G:A	A	0.165514	Lipid	Dihydrosphingomyelins	behenoyl dihydrosphingomyelin (d18:0/22:0)*	-0.123879569	1.20x10 ⁻⁵	0.496557331
<i>CFH</i>	rs76378524	1:196143649:T:C	C	0.067303	Lipid	Primary Bile Acid Metabolism	glycocholate	0.333072077	9.30x10 ⁻⁶	0.432978302
<i>CFH</i>	rs191468419	1:196157574:A:G	G	0.067953	Lipid	Primary Bile Acid Metabolism	glycocholate	0.333072077	9.30x10 ⁻⁶	0.432978302
<i>CFH</i>	rs16839652	1:196165797:C:A	A	0.068044	Lipid	Primary Bile Acid Metabolism	glycocholate	0.333072077	9.30x10 ⁻⁶	0.432978302
<i>CFH</i>	rs2094029	1:196166278:T:C	C	0.068082	Lipid	Primary Bile Acid Metabolism	glycocholate	0.333072077	9.30x10 ⁻⁶	0.432978302
<i>CFH</i>	rs76374435	1:196168664:A:T	T	0.068185	Lipid	Primary Bile Acid Metabolism	glycocholate	0.333072077	9.30x10 ⁻⁶	0.432978302
<i>C6orf15</i>	rs115593773	6:31164763:A:G	G	0.067012	Lipid	Androgenic Steroids	5alpha-androstan-3beta;17beta-diol monosulfate (2)	0.213659162	2.65x10 ⁻⁶	0.19041804
<i>ASPM</i>	rs75797460	1:197039343:G:A	A	0.144775	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotate	0.273978327	1.52x10 ⁻¹⁰	0.000127395
<i>CFH</i>	rs146690273	1:196946050:T:G	G	0.133725	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotate	0.274796975	1.95x10 ⁻¹⁰	0.000127395
<i>ASPM</i>	rs75797460	1:197039343:G:A	A	0.144775	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotidine	0.5106712	1.48x10 ⁻¹⁰	0.000127395
<i>CFH</i>	rs146690273	1:196946050:T:G	G	0.133725	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotidine	0.514214532	1.30x10 ⁻¹⁰	0.000127395
<i>ASPM</i>	rs75797460	1:197039343:G:A	A	0.144775	Nucleotide	Purine Metabolism; (Hypo)Xanthine/Inosine containing	xanthine	0.221634851	5.44x10 ⁻⁸	0.018276974
<i>ASPM</i>	rs111579393	1:196970745:A:C	C	0.148014	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotidine	0.37872223	2.32x10 ⁻⁸	0.012125233
<i>CFH</i>	rs146690273	1:196946050:T:G	G	0.133725	Nucleotide	Purine Metabolism; (Hypo)Xanthine/Inosine containing	xanthine	0.222758661	5.61x10 ⁻⁸	0.018276974
<i>CFH</i>	rs139379775	1:196949463:TATTATC:T	T	0.147855	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotidine	0.380194009	3.57x10 ⁻⁸	0.015513981
<i>ASPM</i>	rs111579393	1:196970745:A:C	C	0.148014	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotate	0.183167006	2.70x10 ⁻⁶	0.19041804
<i>CFH</i>	rs139379775	1:196949463:TATTATC:T	T	0.147855	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotate	0.182783994	4.26x10 ⁻⁶	0.2921833
<i>CFH</i>	rs45489701	1:196952268:C:T	T	0.21982	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotidine	0.234906599	2.14x10 ⁻⁶	0.179789649

<i>CFH</i>	rs78077089	1:196952908:G:A	A	0.219949	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotidine	0.234906599	2.14x10-6	0.179789649
<i>ASPM</i>	rs60002789	1:196954156:T:C	C	0.21594	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotidine	0.234906599	2.14x10-6	0.179789649
<i>ASPM</i>	rs72468006	1:196955060:C:A	A	0.219946	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotidine	0.234906599	2.14x10-6	0.179789649
<i>ASPM</i>	rs75567332	1:196957558:G:A	A	0.220001	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotidine	0.234906599	2.14x10-6	0.179789649
<i>ASPM</i>	rs147817047	1:196957680:A:G	G	0.220002	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotidine	0.234906599	2.14x10-6	0.179789649
<i>ASPM</i>	rs142183523	1:196960752:C:T	T	0.218652	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotidine	0.234906599	2.14x10-6	0.179789649
<i>ASPM</i>	rs111822146	1:196963981:G:A	A	0.220137	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotidine	0.234906599	2.14x10-6	0.179789649
<i>ASPM</i>	rs80119232	1:196966114:C:T	T	0.220149	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotidine	0.234906599	2.14x10-6	0.179789649
<i>ASPM</i>	rs75282993	1:196966223:C:G	G	0.218734	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotidine	0.234906599	2.14x10-6	0.179789649
<i>ASPM</i>	rs78629106	1:196968744:G:A	A	0.220462	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotidine	0.234906599	2.14x10-6	0.179789649
<i>ASPM</i>	rs45445493	1:196978944:G:A	A	0.218855	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotidine	0.234906599	2.14x10-6	0.179789649
<i>CFH</i>	rs3748557	1:196946869:T:A	A	0.218032	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotidine	0.23292319	4.41x10-6	0.294811344
<i>ASPM</i>	rs111379055	1:196977071:T:A	A	0.224493	Nucleotide	Pyrimidine Metabolism; Orotate containing	orotidine	0.24047239	2.38x10-6	0.19041804

rsID: reference single nucleotide polymorphism (SNP) cluster ID; CHRPOS - chromosome position; GPE - glycerophosphatidylethanolamine; PT - Portugal; Meta - results from meta-analysis